Companies /Healthcare

Syndax Pharmaceuticals Inc

NASDAQ: SNDX Biotechnology
$19.54
▼ $0.62 (−3.08%) today
Markets closed · 8:11pm ET

Q3 2025 Earnings

Reported Nov 3, 2025, 4:02pm ET · SEC source
$-0.70
Beat +1.55%
EPS · est. $-0.71
$45.9M
Miss −4.38%
Revenue · est. $48.0M
+30.8%
Beating market
SNDX vs S&P since report
1 quarter
Consecutive EPS misses

Market Reaction

% change · around the report
0+10%+20%+30%Nov 3Nov 4report 4:02pm ETearnings−1.3%+27.5%
0+10%+20%+30%Nov 3Nov 4earnings−1.3%+27.5%
SNDX +27.5%S&P 500 −1.3%
0+10%+20%+30%Nov 3Nov 4report 4:02pm ETearnings−2.3%+27.5%
0+10%+20%+30%Nov 3Nov 4earnings−2.3%+27.5%
SNDX +27.5%NASDAQ −2.3%
0+20%Nov 3Nov 11report 4:02pm ETearnings−0.0%+35.8%
0+20%Nov 3Nov 11earnings−0.0%+35.8%
SNDX +35.8%S&P 500 −0.0%
0+20%Nov 3Nov 11report 4:02pm ETearnings−1.6%+35.8%
0+20%Nov 3Nov 11earnings−1.6%+35.8%
SNDX +35.8%NASDAQ −1.6%
+11.56%
Day of report
−1.63%
Next session
+15.50%
One week
+32.38%
30 days

S&P 500 over the same 30 days: +1.55%.

Did SNDX Beat Earnings? Q3 2025 Results

Syndax Pharmaceuticals delivered a mixed but broadly encouraging third quarter, narrowing its per-share loss to $0.70 against a consensus estimate of $0.71, a 1.55% beat, while revenue of $45.87 million fell 4.38% short of the $47.97 million analysts had expected. The top-line figure was nonetheless striking in context, representing a 267.0% year-over-year surge from the $12.50 million recorded when the company was still pre-commercial. The primary engine behind that growth was Revuforj, its first-in-class menin inhibitor, which generated $32.01 million in net product revenue and saw prescriptions climb 25% sequentially, while collaboration revenue from Niktimvo contributed an additional $13.86 million. Shares jumped roughly 14% following the report, with analysts tightening their loss-per-share outlook for 2026 to $1.25. Looking ahead, Syndax narrowed full-year operating expense guidance to $380 million to $385 million, and management said its $456.13 million cash position, combined with growing product revenue, positions the company to reach profitability without raising additional capital.

Key Takeaways
  • Revuforj net revenue grew 12% sequentially with total prescriptions up 25% quarter-over-quarter to approximately 850
  • Niktimvo net revenue grew 27% sequentially to $45.8 million with 80% of U.S. bone marrow transplant centers having ordered
  • FDA approval of Revuforj for second indication (R/R NPM1m AML) on October 24, 2025
  • Inclusion of revumenib in NCCN Guidelines for R/R NPM1m AML on September 18, 2025
  • R&D expenses declined due to absence of $15 million Niktimvo approval milestone payment from prior year and completion of registrational trial
  • 90% of Niktimvo patients who started in Q1 remain on therapy

“The third quarter was another remarkable period of commercial and pipeline execution for Syndax. Demand remained strong for Revuforj and Niktimvo with over $75 million in combined net sales for the quarter.”

Syndax Pharmaceuticals CEO, on the earnings call

Forward Guidance & Outlook

For full year 2025, the company expects total R&D plus SG&A expenses of $380–$385 million, excluding approximately $45 million in non-cash stock compensation expense, narrowed from prior guidance of $370–$390 million. Syndax expects its operating expense base to remain stable over the next few years and believes its $456.1 million in cash, equivalents and investments, combined with anticipated product revenue and interest income, will enable the company to reach profitability. The company expects to report data from a colorectal cancer trial of revumenib at a medical conference in Q1 2026, complete enrollment in the Phase 2 IPF trial by end of 2025 with topline data anticipated in H2 2026, and initiate the REVEAL trials in newly diagnosed acute leukemia by end of 2025.

SNDX YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$-40,000,000$0$40.0M$12.5M$45.9MRevenue$12.5M$43.8MGross Profit$-42,259,180$-57,426,000Operating Income$-47,496,675$-60,715,000Net Income
$-40,000,000$0$40.0MRevenueGross ProfitOperating IncomeNet Income

SNDX Revenue by Segment

Revuforj (revumenib)$32.0M
Niktimvo (axatilimab-csfr) - Collaboration Revenue
Niktimvo (axatilimab-csfr) - collaboration revenue$13.9M
Niktimvo (axatilimab-csfr)
Milestone, License and Royalty Revenue

Figures from SEC filings and company reports. Not investment advice.